Because Gemini delivers genetic instructions rather than a fixed drug, a single platform can reach many diseases — from chronic-disease therapeutics and oncology to infectious disease and animal health, validated across species.
| Program / area | Modality | Stage | Validation |
|---|---|---|---|
| Long-acting mAb — chronic inflammatory disease | Gemini-D antibody | Preclinical | Multi-species expression data |
| Malaria prophylaxis | Gemini antibody | Preclinical | Partnered with Medicines for Malaria Venture; 6+ mo expression |
| First-in-class oncology — CaV1.4 antibodies | Antibody | IND-directed | Frontiers in Pharmacology (2022) |
| Infectious disease / vaccine | Gemini-R | Preclinical | Nature Communications (2025) — spike Ab, 6-mo |
| Animal health | Gemini vaccines & antibodies | Partnering | $12B global market (partner undisclosed) |
Stages: Discovery → Preclinical → IND-directed → Clinical. Programs and partners disclosed only where permitted.
Because the platform delivers genetic instructions rather than a fixed drug, a single system spans therapeutic antibodies, enzymes, cytokines, and vaccine antigens — across infectious disease, oncology, autoimmune, and rare disease.
Months of antibody from one dose — designed to redose as needed.
Single-dose, season-long protection without a cold chain.
Stronger, longer-lasting responses from smaller doses.
Gemini's performance has been confirmed across mouse, canine, and Yorkshire pig models, with non-human primate studies underway at leading institutions including the Pirbright Institute (UK) and Tulane University (USA). Expression timelines track closely across species — de-risking the path to the clinic.
Evaluate Gemini against your asset through a milestone-gated feasibility study.
Partner With Us →